Clinical trial
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
NCT00168051 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Withdrawn
Key facts
| NCT number | NCT00168051 |
|---|---|
| Title | Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A |
| Official title | A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII) |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Withdrawn |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hemophilia A |
| Intervention type | Drug |
| Interventions | ReFacto, Advante |
| Enrollment | 0 |
| Start date | Apr 1, 2005 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Sep 14, 2005 |
| Last update posted | Sep 25, 2018 |
| Countries | Belgium, France, Germany, Italy, Netherlands, New Zealand, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: